Sage Non Current Liabilities Total vs Common Stock Shares Outstanding Analysis
SAGE Stock | USD 12.01 0.30 2.56% |
Sage Therapeutic financial indicator trend analysis is much more than just breaking down Sage Therapeutic prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sage Therapeutic is a good investment. Please check the relationship between Sage Therapeutic Non Current Liabilities Total and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
Non Current Liabilities Total vs Common Stock Shares Outstanding
Non Current Liabilities Total vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sage Therapeutic Non Current Liabilities Total account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Sage Therapeutic's Non Current Liabilities Total and Common Stock Shares Outstanding is -0.14. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Sage Therapeutic, assuming nothing else is changed. The correlation between historical values of Sage Therapeutic's Non Current Liabilities Total and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Sage Therapeutic are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Current Liabilities Total i.e., Sage Therapeutic's Non Current Liabilities Total and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | -0.14 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Current Liabilities Total
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Sage Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sage Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Selling General Administrative is forecasted to decline to about 144.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 2.9M | 14.2M | 36.1M | 37.9M | Net Interest Income | 2.9M | 14.2M | 36.1M | 37.9M |
Sage Therapeutic fundamental ratios Correlations
Click cells to compare fundamentals
Sage Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sage Therapeutic fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.1B | 2.2B | 1.8B | 1.4B | 882.3M | 873.1M | |
Other Current Liab | 86.6M | 54.9M | 67.3M | 72.7M | 67.3M | 44.1M | |
Total Current Liabilities | 112.1M | 67.2M | 85.2M | 99.3M | 82.7M | 59.3M | |
Total Stockholder Equity | 944.7M | 2.1B | 1.7B | 1.3B | 799.5M | 802.6M | |
Property Plant And Equipment Net | 42.9M | 31.8M | 19.1M | 13.4M | 6.4M | 11.8M | |
Net Debt | (89.6M) | (1.6B) | (275.8M) | (150.6M) | (65.8M) | (69.1M) | |
Retained Earnings | (1.6B) | (1.0B) | (1.5B) | (2.0B) | (2.6B) | (2.4B) | |
Accounts Payable | 15.3M | 3.7M | 10.5M | 19.0M | 10.3M | 11.5M | |
Cash | 126.7M | 1.7B | 294.2M | 162.7M | 71.0M | 67.4M | |
Non Current Assets Total | 49.1M | 36.9M | 24.6M | 84.0M | 12.9M | 20.5M | |
Non Currrent Assets Other | 3.8M | 3.3M | 4.3M | 69.3M | 6.5M | 8.4M | |
Other Assets | 6.2M | 5.1M | 5.5M | 6.0M | 6.9M | 7.3M | |
Cash And Short Term Investments | 1.0B | 2.1B | 1.7B | 1.3B | 753.2M | 829.1M | |
Common Stock Shares Outstanding | 50.8M | 53.0M | 58.7M | 59.3M | 59.8M | 45.7M | |
Liabilities And Stockholders Equity | 1.1B | 2.2B | 1.8B | 1.4B | 882.3M | 873.1M | |
Non Current Liabilities Total | 3.7M | 27.4M | 19.7M | 11.1M | 4.6M | 0.0 | |
Other Current Assets | 26.7M | 22.8M | 58.3M | 50.8M | 31.8M | 20.8M | |
Other Stockholder Equity | 2.6B | 3.1B | 3.2B | 3.3B | 3.4B | 1.8B | |
Total Liab | 139.5M | 86.9M | 96.3M | 103.9M | 82.7M | 70.5M | |
Property Plant And Equipment Gross | 42.9M | 31.8M | 24.1M | 19.5M | 13.9M | 13.2M | |
Total Current Assets | 1.0B | 2.1B | 1.8B | 1.3B | 869.4M | 852.6M | |
Accumulated Other Comprehensive Income | 1.3M | 415K | (2.7M) | (10.2M) | (814K) | (854.7K) | |
Property Plant Equipment | 9.1M | 6.8M | 19.1M | 2.9M | 3.3M | 5.0M | |
Other Liab | 3.7M | 519K | 270K | 100K | 115K | 109.3K | |
Net Tangible Assets | 944.7M | 2.1B | 1.7B | 1.3B | 1.4B | 977.9M | |
Retained Earnings Total Equity | (1.6B) | (1.0B) | (1.5B) | (2.0B) | (1.8B) | (1.7B) | |
Short Term Investments | 881.7M | 438.5M | 1.4B | 1.1B | 682.2M | 630.7M | |
Capital Surpluse | 2.6B | 3.1B | 3.2B | 3.3B | 3.8B | 2.0B | |
Non Current Liabilities Other | 27.4M | 19.7M | 11.1M | 4.6M | 5.3M | 8.5M | |
Net Invested Capital | 944.7M | 2.1B | 1.7B | 1.3B | 799.5M | 1.3B | |
Net Working Capital | 923.0M | 2.1B | 1.7B | 1.2B | 786.6M | 1.3B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.Note that the Sage Therapeutic information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
CEOs Directory Screen CEOs from public companies around the world |
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.39) | Revenue Per Share 1.519 | Quarterly Revenue Growth 1.399 | Return On Assets (0.32) | Return On Equity (0.55) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.